Legacy Kalaris is a clinical-stage biopharmaceutical company developing TH103, a novel anti-VEGF fusion protein designed to treat exudative and neovascular retinal diseases such as neovascular age-related macular degeneration and diabetic macular edema. The drug is engineered for extended intraocular retention through binding to heparan sulfate proteoglycans, potentially reducing injection frequency compared to existing anti-VEGF therapies. Legacy Kalaris generates no current revenue as a development-stage company but plans to commercialize TH103 through its own specialty salesforce if approved, while outsourcing manufacturing to contract partners and potentially licensing or acquiring additional ophthalmologic therapeutics to expand its commercial portfolio.